Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
View/ Open
Date
2017-08-01ICR Author
Author
Gleeson, M
Hawkes, EA
Peckitt, C
Wotherspoon, A
Attygalle, A
Sharma, B
Du, Y
Ethell, M
Potter, M
Dearden, C
Horwich, A
Chau, I
Cunningham, D
Type
Journal Article
Metadata
Show full item recordAbstract
Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003-2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.
Collections
Subject
Humans
Lymphoma, Follicular
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Staging
Treatment Outcome
Combined Modality Therapy
Remission Induction
Hematopoietic Stem Cell Transplantation
Survival Analysis
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Male
Lymphoma, Large B-Cell, Diffuse
Neoplasm Grading
Maintenance Chemotherapy
Rituximab
Antineoplastic Agents, Immunological
Research team
Medicine (RMH Smith Cunningham)
Language
eng
License start date
2017-08
Citation
Leukemia & lymphoma, 2017, 58 (8), pp. 1805 - 1813
Publisher
TAYLOR & FRANCIS LTD